Novartis has raised its full-year guidance after reporting a beat on both profit and sales in the first quarter. The company’s non-GAAP EPS of $1.80 beat consensus expectations by $0.12, while revenue of $11.83 billion beat by $330 million.
Novartis has raised its full-year guidance after reporting a beat on both profit and sales in the first quarter. The company’s non-GAAP EPS of $1.80 beat consensus expectations by $0.12, while revenue of $11.83 billion beat by $330 million.